Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)
- 15 November 2011
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 77 (20), 1801-1807
- https://doi.org/10.1212/wnl.0b013e318237f649
Abstract
Objective: To use the Unified Batten Disease Rating Scale (UBDRS) to measure the rate of decline in physical and functional capability domains in patients with juvenile neuronal ceroid lipofuscinosis (JNCL) or Batten disease, a neurodegenerative lysosomal storage disorder. We have evaluated the UBDRS in subjects with JNCL since 2002; during that time, the scale has been refined to improve reliability and validity. Now that therapies are being proposed to prevent, slow, or reverse the course of JNCL, the UBDRS will play an important role in quantitatively assessing clinical outcomes in research trials. Methods: We administered the UBDRS to 82 subjects with JNCL genetically confirmed by CLN3 mutational analysis. Forty-four subjects were seen for more than one annual visit. From these data, the rate of physical impairment over time was quantified using multivariate linear regression and repeated-measures analysis. Results: The UBDRS Physical Impairment subscale shows worsening over time that proceeds at a quantifiable linear rate in the years following initial onset of clinical symptoms. This deterioration correlates with functional capability and is not influenced by CLN3 genotype. Conclusion: The UBDRS is a reliable and valid instrument that measures clinical progression in JNCL. Our data support the use of the UBDRS to quantify the rate of progression of physical impairment in subjects with JNCL in clinical trials.Keywords
This publication has 22 references indexed in Scilit:
- Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial DesignMovement Disorders, 2010
- Linear clinical progression, independent of age of onset, in Niemann–Pick disease, type CAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2009
- Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X)Clinical Genetics, 2009
- Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?Nature Reviews Neurology, 2009
- The transmembrane topology of Batten disease protein CLN3 determined by consensus computational prediction constrained by experimental dataFEBS Letters, 2008
- Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeatJournal of Neurology, Neurosurgery & Psychiatry, 2008
- A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosisHuman Molecular Genetics, 2007
- Splicing in disease: disruption of the splicing code and the decoding machineryNature Reviews Genetics, 2007
- Homogeneous Polymerase Chain Reaction Nucleobase Quenching Assay to Detect the 1-kbp Deletion in CLN3 That Causes Batten DiseaseThe Journal of Molecular Diagnostics, 2004
- Genomic Structure and Complete Nucleotide Sequence of the Batten Disease Gene,CLN3Genomics, 1997